Of note, a cohort of 26 invasive breast cancer patients, which represents about 18.8% and 3.4% of the total SIRT6 and ERBB2 gene amplifications, respectively, harbors a concomitant gene amplification of both SIRT6 and ERBB2 (Fig. 5A). This evidence concerns the gene ERBB2 and invasive breast carcinoma.